To receive updates on all the latest information on ImmunID, please register by entering your email address below:
The news letter is only currently available in French, we thank you for your understanding.
To get the entire content of the newsletter, we invite you to visit our Blog: http://immunid-blog.com/
Press Release - January 2012 ImmunID at the 34th CTRC-AACR San Antonio Breast Cancer Symposium.
ImmunID participated in this major breast cancer conference, for which the main themes were emerging treatments in difficult-to-treat populations, including patients with metastatic cancer, and new knowledge about risk and prevention. See more... Go to blog
Press Release - November 2011 ImmunID Technologies Announces Divpenia® Poster Presentation at the 34 th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Grenoble, Lyon (France), Nov. 28, 2011 – ImmunID, the immune repertoire diversity company, today announced a presentation at the 34 th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The event will be held on December 6-10, 2011 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Press Release - October 2011 Pink October, ImmunID Enters Into The Battle Against Breast Cancer .
Today ImmunID has justified hopes that its biomarker, Divpenia, will become a tool providing clinical teams with information enabling them to predict the efficacy of therapy.
Press Release - October 2011 ImmunID, the immune repertoire diversity company, will present at the 19th Annual BioPartnering Europe, QEII Conference Centre, London.
On Tuesday, october 11 , 2011 at Biopartnering Europe, Delphine Davan, in charge of Business Development Europe at ImmunID, will provide an introduction to the company’s biomarker, divpenia®, and on ImmunID’s latest achievements in stratifying and monitoring patients suffering from Infectious Diseases and Cancer.
Press Release - September 2011 ImmunID, the immune repertoire diversity company, has been invited to present at Two Upcoming Conferences : European Cancer Cluster Partnering - Toulouse, France &French Biotech Tour - Cambridge, MA, USA
On Thursday September 15, 2011 at ECCP in Toulouse, Dr Christophe Caux, Senior Scientist at INSERM and at the Leon Bérard Center (Lyon) and Nadia Plantier, Director of External Collaborations and Business Development at ImmunID, will give a joint presentation on the current collaboration between the Leon Bérard Center and ImmunID. The talk will focus on the investigation of ImmunID’s innovative biomarker, divpenia®, as a prognostic factor in metastatic Breast Cancer.
On Wednesday September 21, 2011 at the French Biotech Tour in Cambrige, MA, Isabelle Tanneau, Scientific Sales Manager at ImmunID, will provide an introduction to the company’s biomarker, divpenia®, and on ImmunID’s latest achievements in stratifying and monitoring patients suffering from Infectious Diseases and Cancer.
Press Release - May 2011 Cytheris, ImmunID Technologies and the Centre Léon Bérard announce the start of DivRescue, a collaborative R&D project principally funded by the 11th FUI call for projects (Interministries fund)
The DivRescue project aims to develop a new protocol for cancer patient management, evaluating immune status and, when necessary, stimulating immune reconstitution. This world-first relies on the synergy between the three main actors: two biotechnology companies ImmunID Technologies and Cytheris – leaders in immunology, diagnostics and pharmacy – and the Centre Léon Bérard, a pioneer in research into cancer-related See more... Go to blog
Press Release - May 2011 Cytheris, Centre Léon Bérard and ImmunID Announce Initiation of Clinical Trial to Evaluate Combination Regimen of IL-7 (CYT107) and XELODA® (capecitabine) in Treatment of Metastatic Breast Cancer
Paris, Lyon, and Grenoble (France) – May 11, 2011 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard (Lyon), the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS (Grenoble), a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial... See more... Go to blog
Le Quotidien du Médecin - April 2011 A new test for routine assessment of immune defenses.
Its name: Divpenia. Its role: to estimate a patient's "immune shield" or defense capacity. Doctors are starting to take an interest, and it has already attracted the pharmaceutical industry. See more...(French) See more...(English) Go to blog
Press Release - April 2011 We are happy to announce that ImmunID has attended the 102nd Annual American Association for Cancer Research (AACR) Meeting on April 2-6 in Orlando, Florida, where we presented our poster “Low TCR diversity (Divpenia®) is a new prognosis factor of overall survival in metastatic breast cancer”. See more... Go to blog
Press Release - March 2011 ImmunID announces the successful validation of its IFS4 Immune Forecast Station on a Roche Diagnostics France quantitative 480 PCR system.
ImmunID has established a technical collaboration for quantitative PCR with Roche Diagnostics France as part of its program for the industrialization and standardization of its 4th generation IFS stations. The aim of this collaboration was to qualify an IFS4 used in the Infectiology Center in Lyon by members of the Platine consortium. The project was succesfull in... See more... Go to blog
Bulletin SFI - Janvier 2011 Quatre «Prix meilleur poster», en partenariat avec la société ImmunID, ont été décernés à : Javier Celis-Gutierrez «Adaptateurs ou acteurs de l’encodage du signal NK», Sandrine Luce «Gènes co-exprimés par les cellules T CD8+ spécifiques de peptides de l’insuline chez les patients atteints de diabète de type 1», Delphine Sauce «La progression dans la pathologie VIH est associée à un épuisement de la lymphopoïèse amplifiée par l’activation immunitaire persistante sous-jacente» et Nathalie Kersual «Anti-tumor effect of an anti-human mullerian inhibiting substance type II receptor antibody in mouse models for ovarian cancer: towards a new targetd therapy».
La rédaction félicite très chaleureusement les lauréats et les remercie d’avoir préparé un résumé de leurs travaux pour cette édition du bulletin. See more... Go to blog
Site Economique - 7 October 2010 ImmunID signe un accord de collaboration avec les Hospices civils de Lyon
et lance la 1ère inclusion de l'étude clinique RIPAL See more... Go to blog
BioFutur Mai 2010 ImmunID et Roche Diagnostics France engagent une collaboration technique See more... Go to blog
Press release - Mars 2010 ImmunID and Roche Diagnostics France establish a technical collaboration with a view to standardizing Immunomonitoring through molecular biology See more...
CEA le mensuel- Novembre 2009 ImmunID, une nouvelle voie dans le bio-médical See more...
Press release.- June 15th 2009 Innate Pharma, Transgene, ImmunID, Inserm and the cancer hospital Centre Léon-Bérard announced the operational start of PLATINE, a joint immuno-monitoring platform See more...
Biotech et Finances.- 08 Juin 2009- N° 421 ImmunID clôt son premier appel de capital à 2,4 ME"
C'est un pas important pour la biotech grenobloise ! ImmunID, spécialiste du diagnostic du répertoire immunitaire, vient de boucler son premier tour de table auprès de la communauté financière française. See more...
Courrier Cadre – avril 2009- N° 29 Ces jeunes pousses à l’avenir prometteur
ImmunID – Un temps d’avance sur la maladie See more...
ACIES – March 2009- N° 29 Challenges
we were the first biotech company in France to benefit from an advance on subsidies... See more...
Biotech et Finances.- 16 février 2009- N° 406 Grenoble : ImmunID conforte son axe "médecine personnalisée"
Créée en 2005 par Sébastien Weisbuch et Nicolas Pasqual, la Biotech Grenobloise ImmunID est leader de l'analyse génétique de la diversité combinatoire du répertoire immuntiaire See more...
Biotech et Finances.- 14 juillet 2008- N° 383 Grenoble : ImmunID ouvre la voie du préfinancement de subventions
Une telle mesure est attendue depuis plusieurs mois par les bioentrepreneurs. Oséo leur permet désormais de disposer d'une avance sur les subventions qu'ils ont officiellement reçues, mais dont le montant ne sera pas crédité avant 6 à 9 mois en moyenne du fait des longueurs administratives. See more...
La tribune de l’Isère – 5 au 11 mai 2008 ImmunID : La météo immunitaire
Biotechnologie. Située dans l’enceinte du CEA à Grenoble, ImmunID Technologies développe des produits innovants permettant de mesurer le bouclier immunitaire d’un patient.
Biotech et Finances • 21 avril 2008 • N° 372 ImmunID surfe sur le courant porteur de l'immunomonitoring
Les start-up du diagnostic étaient les dernières de la classe en matière de financement. Elles deviennent attractives et pourraient même s’inscrire en pole pos i t ion avec des Biomarqueurs qui deviennent incontournables dans l’analyse des médicaments et vaccins. See more...
Posted January 14, 2008 ImmunID Technologies signed a Service Research Contract with Sanofi Pasteur
ImmunID Technologies announced today the signature of a Contract Research Service with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and the largest worldwide company entirely devoted to human vaccines.
See more...
OptionBio - Lundi 15 octobre 2007 – N° 389 Tests génétiques, marqueurs biologiques d’efficacité et suivi immunologique pour la sécurité des traitements
Les laboratoires hospitaliers d’immunologie manquent de moyens et sont à la recherche de tests simples utilisables par les praticiens biologistes et donnant des résultats rapides, par la création d’un répertoire immunitaire. See more…laisser la possibilité d’ouvrir le pdf correspondant See more...
Présence – Mai 2007 ImmunID Technologies teste l’immunité
En deux petites années, la société de biotechnologies a fait la preuve de son concept, réalisé ses premières ventes et commaboré avec des laboratoires de grande pointure.
Biotech.Info- 17 janvier 2007- N° 339 ImmunID, tout le répertoire immunitaire
Le concept d’ImmunID : démocratiser l’analyse immunitaire, jusqu’ici réservée aux académiques et aux grands groupes. La société se développe dans le service et bientôt dans les kits de diagnostic.
See more...
Reference Innovation – October 2006- N°4 ImmunID Technologies: a Biotech that claims “immune signature revealed”
Why an “Immune system weather forecast”? To describe changes in the immune system at a particular
moment...and make forecasts for the months to come. Its use?
Estimate the diversity of an individual's immune repertoire to assess its “white cell police”, modifications of which are associated with a large number of pathologies. See more...
Courrier Cadre – avril 2009- N° 29
